- Report
- May 2024
- 50 Pages
Global
From €2518EUR$2,650USD£2,166GBP
- Report
- May 2024
- 50 Pages
Europe
From €1805EUR$1,900USD£1,553GBP
- Report
- December 2021
- 132 Pages
Global
From €808EUR$850USD£695GBP
- Report
- January 2024
- 287 Pages
Global
From €3392EUR$3,570USD£2,918GBP
- Report
- March 2021
- 202 Pages
Global
From €3471EUR$3,654USD£2,986GBP
- Report
- July 2023
- 140 Pages
Global
From €5699EUR$5,999USD£4,903GBP
- Report
- May 2023
- 147 Pages
Global
From €5699EUR$5,999USD£4,903GBP
- Report
- April 2023
- 147 Pages
Global
From €5699EUR$5,999USD£4,903GBP
- Report
- April 2023
- 147 Pages
Global
From €5699EUR$5,999USD£4,903GBP
- Book
- August 2021
- 304 Pages
- Book
- April 2018
- 368 Pages
- Book
- October 2012
- 400 Pages
- Book
- October 2010
- 606 Pages
- Book
- February 2010
- 978 Pages
The Human Albumin market is a subset of the biotechnology industry that focuses on the production and sale of human albumin, a protein found in human blood plasma. Human albumin is used in a variety of medical treatments, including the treatment of shock, burns, and other trauma-related conditions. It is also used in the production of a variety of pharmaceuticals, including vaccines and drugs.
The Human Albumin market is highly regulated, with strict standards for quality and safety. Companies in the market must adhere to stringent regulations and guidelines set by the US Food and Drug Administration (FDA) and other regulatory bodies.
The Human Albumin market is highly competitive, with a number of companies competing for market share. Companies in the market include CSL Behring, Grifols, Octapharma, Kedrion, and Biotest. Show Less Read more
